Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice

Annals of Oncology

Volumn 19, Issue 9, 2008, Pages 1584-1591

  Zhong, Q ^a   Wen, Y J ^b   Yang, H S ^b   Luo, H ^a   Fu, A F ^b   Yang, F ^a   Chen, L J ^b   Chen, X ^b   Qi, X R ^a   Lin, H G ^b   Wan, Y ^b   Chen, X C ^b   Wei, Y Q ^b   Zhao, Xia ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Apoptosis; Cisplatin resistant; Ovarian cancer; Vesicular stomatitis virus matrix protein (VSVMP)

Indexed keywords

CISPLATIN; LIPOSOME; MATRIX PROTEIN; PLASMID DNA; VESICULAR STOMATITIS VIRUS MATRIX PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PRIORITY JOURNAL; VESICULAR STOMATITIS VIRUS; XENOGRAFT;

EID: 50849100993     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn167     Document Type: Article

References (30)

1. Ozols RF, Bookman MA, Connolly DC et al. Focus on epithelial ovarian cancer. Cancer Cell 2004; 5: 19-24.
2. Koyama AH. Induction of apoptotic DNA fragmentation by the infection of vesicular stomatitis virus. Virus Res 1995; 37: 285-290.
3. Balachandran S, Barber GN. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 2004; 5: 51-65.
4. Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease. J Virol 2002; 76: 895-904.
5. Ebert O, Shinozaki K, Huang TG et al. Oncolylic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 2003; 63: 3605-3611.
6. Blondel D, Harmison GG, Schubert M. Role of matrix protein in cytopathogenesis of vesicular stomatitis virus. J. Virol 1990; 64: 1716-1725.
7. Melki R, Gaudin Y, Blondel D. Interaction between tubulin and the viral matrix prolein of vesicular stomatitis virus: Possible implications in the viral cytopathic effect. Viroiogy 1994; 202: 339-347.
8. Black BL, Lyles DS. Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. J Virol 1992; 66: 4058-4064.
9. Black BL, Rhodes RB, McKenzie M, Lyles DS. The role of vesicular stomatitis virus matrix protein in inhibition of host-directed gene expression is genetically separable from its function in virus assembly. J Virol 1993; 67: 4814-4821.
10. Kopecky SA, Willingham MC, Lyles DS. Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol 2001; 75: 12169-12181.
11. Kopecky SA, Lyles DS. The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J Virol 2003; 77: 5524-5528.
12. Lin XJ, Chen XC, Wei YQ et al. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged swvival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecol Oncol 2007; 104: 540-546.
13. Louie KG, Behrens BC, Kinsella TJ et al. Radiation survival parameters of antineoplastic drug-serisitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 1985; 45: 2110-2115.
14. Wei YQ, Zhao X, Kariya Y et al. Inhibition of proliferation and induction of apoptosis by abrogation of heat-shock protein (HSP)70 expression in tumor cells. Cancer Immunol Immun 1995; 40: 73-78.
15. Wei YQ, Zhao X, Kariya Y et al. Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res 1994; 54: 4952-4957.
16. Lee TK, Man K, Ho JW et al. FFY720: A promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res 2005; 11: 8458-8466.
17. Roberts WG, Whalen PM, Soderstrom E et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res 2005; 65: 957-966.
18. Nowell PC. Mechanisms of tumor progression. Cancer Res 1986; 46: 2203-2207.
19. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34: 1535-1542.
20. Henkels KM, Turchl JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999: 59: 3077-3083.
21. Liu JR, Opipari AW, Tan L et al. Dysfunctional apoptosomal activation in ovarian cancer: Implications for chemoresistance. Cancer Res 2002; 62: 924-931.
22. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000; 60: 5659-5666.
23. Letchworth GJ, Rodriguez LL, Del CBJ. Vesicular stomatitis. Vet J 1999; 157: 239-260.
24. ewdell JW, Bennink JR, Mackett M et al. Recognition of cloned vesicular stomatitis virus internal and external gene products by cytotoxic T lymphocytes. J Exp Med 1986; 163: 1529-1538.
25. Puddington L, Bevan MJ, Rose JK, Lefrançois L. N protein is the predominant antigen recognized by vesicular stomatitis virus-specific cytotoxic T cells. J Virol 1986; 60: 708-717.
26. Kalinke U, Bucher EM, Ernst B et al. The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus. Immunity 1996; 5: 639-652.
27. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
28. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
29. Dixelius J, Larsson H, Sasaki T et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000; 95: 3403-3411.
30. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003; 13:159-167.